NOS2 has been demonstrated to possess anti-tumoricidal functions and to predict poor patient outcomes in several cancer types, including stomach and colon cancer, as it correlates with increased vascularization and metastasis (Thomas and Wink 2017). This evidence concerns the gene NOS2 and colonic neoplasm.